Delcath Systems, Inc. (DCTH)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$16.480.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Delcath aims to grow revenue to at least $100 million in 2026. Gross margins are expected to stay high between 84% and 87%. The company is on track to improve profitability with a goal of positive adjusted EBITDA. Share buybacks show management's confidence in the business.
Revenue could fall short of the $100 million target, hurting growth expectations. High valuation with a PE near 863 times earnings risks a sharp correction. Profitability goals may not be met if costs rise or sales slow.
The price is about 36% above our fair value near $10. Analysts expect revenue to decline 60%, which contrasts with management's growth targets. Our view is more optimistic on revenue and margins.
Breaks if: Gross margin falls below 84% in FY26
Sustain full year gross margins in the range of 84% to 89% for fiscal year 2026.
Stated as a priority in 3 of last 3 quarters. Gross margins improved from 85% in 2026-Q1 to 90% in 2026-Q2, exceeding the guidance range which was updated from 84%-87% to 86%-89%. The trajectory shows delivering and slight improvement beyond prior guidance.
“Full year gross margins in the range of 86% to 89%”
“Gross margins in the range of 84% to 87%”
“Gross margins in the range of 84% to 87%”
Breaks if: Adjusted EBITDA remains negative through FY26
Delcath aims to achieve positive adjusted EBITDA for the fiscal year 2026.
Breaks if: Revenue falls below $100M in FY26
Deliver total CHEMOSAT and HEPZATO KIT revenue of at least $100 million in fiscal year 2026, reflecting growth in HEPZATO KIT volume.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $19.8 million in 2025-Q1 to $29.1 million in 2026-Q2. Management increased 2026 revenue guidance from at least $100 million to a range of $104 million to $108 million, reflecting at least 28% growth in HEPZATO KIT volume over 2025. The trajectory is delivering consistent growth and upward guidance.
“2026 Revenue Guidance to a Range of $104M to $108M”
“Total CHEMOSAT and HEPZATO KIT revenue to be at least $100 million, reflecting an increase in HEPZATO KIT volume of at least 20% over 2025”
“Total CHEMOSAT and HEPZATO KIT revenue to be at least $100 million”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. DCTH has shown strong recent financial performance, but it is still loss-making and carries elevated risks, making it a more volatile option for investors.
The market currently prices DCTH at an expensive valuation compared to its peers, reflecting expectations of continued strong performance. However, there is a noted expectations gap, suggesting that the current price may not fully account for potential challenges ahead.
Management is on track to achieve its revenue and adjusted EBITDA goals for 2026, indicating improving operational profitability. However, gross margins are mixed, which may affect overall financial health in the near term.
The long-term thesis hinges on management's ability to maintain guidance and deliver on revenue targets. Additionally, external factors such as sector performance and economic conditions will significantly impact DCTH's trajectory.
In the next 1 to 3 years, DCTH's performance will depend on its execution of strategic priorities and external market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the company's growth outlook. Additionally, Delcath raised its 2026 revenue guidance to $104 million to $108 million. This increase reinforces confidence in achieving at least $100 million in revenue for the year.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.